2C-T-7

Dialog-warning.svg.png

Serious injury or death may occur if 2C-T-7 is insufflated or combined with certain substances and medications (e.g. MAOIs or RIMAs)[1][2][3]

It is strongly discouraged to insufflate (snort), eyeball, administer non-orally, or combine this substance with certain other substances. Please see this section for more details.

Summary sheet: 2C-T-7
2C-T-7
2C-T-7.svg
Chemical Nomenclature
Common names 2C-T-7, Beautiful, Blue Mystic, 7th Heaven
Substitutive name 2,5-Dimethoxy-4-(propylthio)phenethylamine
Systematic name 2-[2,5-Dimethoxy-4-(propylsulfanyl)phenyl]ethan-1-amine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Threshold 3 mg
Light 10 - 15 mg
Common 15 - 25 mg
Strong 25 - 40 mg
Heavy 40 mg +
Duration
Total 6 - 10 hours
Onset 60 - 90 minutes
Come up 10 - 30 minutes
Peak 3 - 5 hours
Offset 1 - 3 hours
After effects 2 - 8 hours



⇣ Insufflated
Dosage
Threshold 1 mg
Light 2 - 5 mg
Common 5 - 10 mg
Strong 10 - 15 mg
Heavy 15 - 25 mg 2C-T-7 has been fatal when insufflated at heavy doses of 30mg or higher.
Duration
Total 3 - 7 hours
Onset 5 - 15 minutes
Come up 20 - 60 minutes
Peak 2 - 4 hours
Offset 1 - 2 hours
After effects 1 - 2 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions


2,5-Dimethoxy-4-propylthiophenethylamine (also known as 2C-T-7, Blue Mystic,[4] and Beautiful,[4] among others) is a psychedelic substance of the phenethylamine chemical class that produces psychedelic and entactogenic effects when administered.

2C-T-7 was first synthesized by Alexander Shulgin and documented in his book PiHKAL ("Phenethylamines I Have Known and Loved").[5] It is a member of the 2C-x family of psychedelic phenethylamines, all of which were derived from the systematic modification of the mescaline molecule.

In contrast to other members of the 2C-x family, 2C-T-7 has gained a reputation of being an unpredictable, dose-sensitive psychedelic capable of producing strong visual effects and an intense body load, which can manifest as a dangerous delirium in extreme cases. Many reports indicate that the physical effects are too severe for inexperienced users or those with pre-existing medical conditions.

This particular compound is part of the so-called "magical half-dozen" which refers to Shulgin's self-rated most important phenethylamine compounds, all of which -- with the exception of mescaline -- he designed, synthesized and tested on himself. They can be found within the first book of PiHKAL, and are as follows: Mescaline, DOM, 2C-B, 2C-E, 2C-T-2 and 2C-T-7.[6]

Chemistry

2C-T-7, or 2,5-dimethoxy-4-propylthiophenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain.

2C-T-7 belongs to the 2C family of phenethylamines, which contain methoxy functional groups CH3O- attached to carbons R2 and R5 of the benzene ring. 2C-T-7 is also substituted at R4 with a propyl thioether group.

2C-T-7 is analogous to 2C-T-2; the two differ by the length of the alkane chain in their thioether functional group.[5]

Pharmacology

Further information: Serotonergic psychedelic

2C-T-7's psychedelic effects have been shown to come from its efficacy at the 5-HT2A receptor as a partial agonist.[7] However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

With serious adverse effects seen on overdoses of this compound (potentially Serotonin Syndrome) and as the 2,5-desmethoxy derivative of 2C-T-7 has been shown to be a moderate monoamine oxidase A inhibitor[8] and many of the amphetamine-analogs of the 2C-T-x series are highly selective MAO-A inhibitors (with ALEPH-7 being one of the most potent)[9], this substance is widely thought to also have MAOI effects.

Subjective effects

 
 This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
 

Visual effects
 

Cognitive effects
 

Auditory effects
 

Transpersonal effects
 

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

 

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

As of August 2007, there have been at least three reported deaths associated with the use of 2C-T-7. These incidents occurred with insufflated doses of 30 mg or more[10], or in combination with stimulants such as MDMA,[citation needed]. There have also been a number of reports describing concerning physical side effects and hospitalizations, typically following insufflation.[11]

It is strongly discouraged to administer 2C-T-7 non-orally because this can cause vomiting, numerous negative side effects, or death at high doses. In Erowid's Fall 2000 2C-T-7 survey, it was reported that the insufflation of 2C-T-7 resulted in more negative side effects than oral administration.[citation needed]

It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.

Tolerance and addiction potential

2C-T-7 is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 2C-T-7 is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 2C-T-7 presents cross-tolerance with all psychedelics, meaning that after the consumption of 2C-T-7 all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

If 2C-T-7 does have MAOI effects as commonly speculated, this could indicate that 2C-T-7 is more likely to induce serotonin syndrome or general neurotransmitter overload (especially at high dosages) than other serotonergic psychedelics.[12] This may make it dangerous to combine it with other MAOIs, stimulants and certain substances which releases neurotransmitters such as serotonin or dopamine. These substances include but are not limited to:

Legal status

In November 2003, the European Council decided that 2C-T-7 shall be subjected by the Member States to control measures and criminal penalties within three months.[13]

  • Australia: In Australia, 2C-T-2 and 2C-T-7 are covered by the country's analog drug laws.[citation needed]
  • Austria: 2C-T-7 is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)[citation needed]
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[14]
  • Canada: 2C-T-7 is considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[15]
  • China: As of October 2015 2C-T-7 is a controlled substance in China.[16]
  • Germany: 2C-T-7 is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[17] as of July 1, 2001.[18] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[19]
  • Latvia: 2C-T-7 is a Schedule I controlled substance in Latvia.[20]
  • The Netherlands: The Netherlands was the first country in the world to ban 2C-T-7 after being sold in smart shops for a short period. After 2C-T-2 was first banned, 2C-T-7 quickly appeared on the market but was soon banned as well. 2C-T-7 is a list I drug of the Opium Law.[citation needed]
  • Sweden: The drug is Schedule I in Sweden.[21] 2C-T-7 was first classified as a health hazard under the act "Lagen om förbud mot vissa hälsofarliga varor" (translated as "the Act on the Prohibition of Certain Goods Dangerous to Health") that made it illegal to sell or possess as of April 1, 1999.[citation needed]
  • Switzerland: 2C-T-7 is a controlled substance specifically named under Verzeichnis D.[22]
  • United Kingdom: 2C-T-7 is a Class A drug in the United Kingdom as a result of the phenethylamine catch-all clause.[23]
  • United States: On September 20, 2002, 2C-T-7 was classified as a Schedule I substance in the United States by an emergency ruling by the DEA. On March 18, 2004, the DEA published a final rule in the Federal Register which permanently placed 2C-T-7 in Schedule I.[citation needed]

See also

Literature

  • Hardison, C. (2000). An amateur qualitative study of 48 2C-T-7 subjective bioassays. MAPS Bulletin, 10(11).

External links

Discussion

References

  1. ↑ "Third Confirmed 2C-T-7 Death". Erowid. April 10, 2001. 
  2. ↑ "A Reported 2C-T-7 Death". Erowid. July 2003. 
  3. ↑ "Second Reported 2C-T-7 Death". Erowid. April 2, 2001. 
  4. ↑ 4.0 4.1 Zimmerman, M. M. (July 2001). "The identification of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)". Microgram. Vol. XXXIV (7). Drug Enforcement Administration (DEA). pp. 169–173. 
  5. ↑ 5.0 5.1 Alexander Shulgin; Ann Shulgin (1991). "#43. 2C-T-7". PiHKAL: A Chemical Love Story. United States: Transform Press. ISBN 0963009605. OCLC 1166889264. 
  6. ↑ Alexander Shulgin; Ann Shulgin (1991). PiHKAL: A Chemical Love Story. United States: Transform Press. ISBN 0963009605. OCLC 1166889264. 
  7. ↑ Fantegrossi, W. E.; Harrington, A. W.; Eckler, J. R.; Arshad, S.; Rabin, R. A.; Winter, J. C.; Coop, A.; Rice, K. C.; Woods, J. H. (2005). "Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats". Psychopharmacology. 181 (3): 496–503. doi:10.1007/s00213-005-0009-4. eISSN 1432-2072. ISSN 0033-3158. OCLC 2409222. PMID 15983786. 
  8. ↑ Wagmann, Lea; Brandt, Simon D.; Stratford, Alexander; Maurer, Hans H.; Meyer, Markus R. (2019). "Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases". Drug Testing and Analysis. 11 (2): 318–324. doi:10.1002/dta.2494. ISSN 1942-7603. 
  9. ↑ Gallardo-Godoy, A.; Fierro, A.; McLean, T. H.; Castillo, M.; Cassels, B. K.; Reyes-Parada, M.; Nichols, D. E. (2005). "Sulfur-Substituted α-Alkyl Phenethylamines as Selective and Reversible MAO-A Inhibitors:  Biological Activities, CoMFA Analysis, and Active Site Modeling". Journal of Medicinal Chemistry. 48 (7): 2407–2419. doi:10.1021/jm0493109. eISSN 1520-4804. ISSN 0022-2623. OCLC 39480771. PMID 15801832. 
  10. ↑ Curtis, B.; Kemp, P.; Harty, L.; Choi, C.; Christensen, D. (2003). "Postmortem Identification and Quantitation of 2,5-Dimethoxy-4-n-propylthiophenethylamine Using GC-MSD and GC-NPD". Journal of Analytical Toxicology. 27 (7): 493–498. doi:10.1093/jat/27.7.493. eISSN 1945-2403. ISSN 0146-4760. OCLC 02942106. PMID 14607005. 
  11. ↑ "2C-T-7 Overdoses & Delirium". Erowid. June 15, 2000. 
  12. ↑ Gallardo-Godoy, A.; Fierro, A.; McLean, T. H.; Castillo, M.; Cassels, B. K.; Reyes-Parada, M.; Nichols, D. E. (2005). "Sulfur-Substituted α-Alkyl Phenethylamines as Selective and Reversible MAO-A Inhibitors:  Biological Activities, CoMFA Analysis, and Active Site Modeling". Journal of Medicinal Chemistry. 48 (7): 2407–2419. doi:10.1021/jm0493109. eISSN 1520-4804. ISSN 0022-2623. OCLC 39480771. PMID 15801832. 
  13. ↑ "COUNCIL DECISION 2003/847/JHA". Official Journal of the European Union. Office for Official Publications of the European Communites (published December 6, 2003). November 27, 2003. pp. 64–65. OCLC 52224955. L 321. 
  14. ↑ "RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016" (in Portuguese). Agência Nacional de Vigilância Sanitária (ANVISA) [Brazilian Health Regulatory Agency (ANVISA)]. December 5, 2016. 
  15. ↑ "Schedule III". Controlled Drugs and Substances Act (CDSA). Isomer Design. Retrieved October 10, 2020. 
  16. ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). 国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]. September 27, 2015. Archived from the original on September 6, 2017. 
  17. ↑ "Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  18. ↑ "Fünfzehnte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (PDF). Bundesgesetzblatt Jahrgang 2001 Teil I Nr. 28 (in German). Bundesanzeiger Verlag (published June 25, 2001). June 19, 2001. pp. 1180–1201. ISSN 0341-1095. OCLC 231871244. 
  19. ↑ "Gesetz über den Verkehr mit Betäubungsmitteln: § 29" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  20. ↑ "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020. 
  21. ↑ "Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 1997:12) om förteckningar över narkotika" (PDF) (in Swedish). Läkemedelsverket [Medical Products Agency] (published March 16, 2004). February 24, 2004. ISSN 1101-5225. LVFS 2004:3. Archived from the original (PDF) on June 13, 2018. 
  22. ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  23. ↑ "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020. 


Retrieved from ‘https://psychonautwiki.org/w/index.php?title=2C-T-7&oldid=146540’